These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 24033646)
1. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. Sunaga T; Suzuki S; Kogo M; Kurihara T; Kaji S; Koike N; Harada N; Suzuki M; Kiuchi Y Eur J Cancer Care (Engl); 2014 May; 23(3):394-400. PubMed ID: 24033646 [TBL] [Abstract][Full Text] [Related]
2. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736 [TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M; Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730 [TBL] [Abstract][Full Text] [Related]
4. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506 [TBL] [Abstract][Full Text] [Related]
5. [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer]. Maruyama T; Yasuda K; Sako A; Ueda K; Okumura M Gan To Kagaku Ryoho; 2016 Jan; 43(1):69-72. PubMed ID: 26809528 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer. Hong KD; Lee SI; Moon HY Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527 [TBL] [Abstract][Full Text] [Related]
7. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer. Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025 [TBL] [Abstract][Full Text] [Related]
8. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. Bin Q; Li J; Liao C; Cao Y; Gao F Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863 [TBL] [Abstract][Full Text] [Related]
9. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767 [TBL] [Abstract][Full Text] [Related]
10. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195 [TBL] [Abstract][Full Text] [Related]
11. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584 [TBL] [Abstract][Full Text] [Related]
12. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215 [TBL] [Abstract][Full Text] [Related]
13. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P Eur J Cancer; 2014 Nov; 50(17):2966-74. PubMed ID: 25266443 [TBL] [Abstract][Full Text] [Related]
14. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K; Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641 [TBL] [Abstract][Full Text] [Related]
15. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival. Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554 [TBL] [Abstract][Full Text] [Related]
16. Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer. Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H Anticancer Res; 2006; 26(2B):1377-83. PubMed ID: 16619547 [TBL] [Abstract][Full Text] [Related]
17. Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan. Yu YL; Tseng WK; Liao CK; Yeh CY; Chen HH; Liu YH; Liaw YW; Fan CW BMC Cancer; 2023 Sep; 23(1):900. PubMed ID: 37749535 [TBL] [Abstract][Full Text] [Related]
18. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study. Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158 [TBL] [Abstract][Full Text] [Related]
19. [Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer]. Sadahiro S; Suzuki T; Maeda Y; Makuuchi H; Murayama C Gan To Kagaku Ryoho; 2006 Mar; 33(3):333-6. PubMed ID: 16531713 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]